Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

About the Cover

March 2023; Volume 43,Issue 3

Special Issue on New Anticancer Agents

Reviews

  • Open Access
    Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators
    JEROME H. CHECK, TRINA PORETTA, DIANE CHECK and MAYA SRIVASTAVA
    Anticancer Research March 2023, 43 (3) 951-965; DOI: https://doi.org/10.21873/anticanres.16240
  • Open Access
    Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
    IOANNIS A. VOUTSADAKIS and ATHINA STRAVODIMOU
    Anticancer Research March 2023, 43 (3) 967-981; DOI: https://doi.org/10.21873/anticanres.16241
  • Open Access
    The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma
    PEDRO CAETANO PINTO
    Anticancer Research March 2023, 43 (3) 983-991; DOI: https://doi.org/10.21873/anticanres.16242
  • Open Access
    Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights
    SABRINA BIMONTE, GIUSEPPE PALMA, MARCO CASCELLA and ARTURO CUOMO
    Anticancer Research March 2023, 43 (3) 993-1000; DOI: https://doi.org/10.21873/anticanres.16243

Experimental Studies

  • Open Access
    7,8-Diacetoxy-3-(4-methylsulfonylphenyl)-4-phenylcoumarin Induces ROS-dependent Cell Death in the A549 Human Lung Cancer Cell Line
    MUSILIYU A. MUSA and QUDUS KOLAWOLE
    Anticancer Research March 2023, 43 (3) 1001-1007; DOI: https://doi.org/10.21873/anticanres.16244
  • Open Access
    Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer
    MIKIKO TAKEBAYASHI KANO, TOSHIO KOKURYO, TAISUKE BABA, KIMITOSHI YAMAZAKI, JUNPEI YAMAGUCHI, MASAKI SUNAGAWA, ATSUSHI OGURA, NOBUYUKI WATANABE, SHUNSUKE ONOE, KAZUSHI MIYATA, TAKASHI MIZUNO, KAY UEHARA, TSUYOSHI IGAMI, YUKIHIRO YOKOYAMA, TOMOKI EBATA and MASATO NAGINO
    Anticancer Research March 2023, 43 (3) 1009-1016; DOI: https://doi.org/10.21873/anticanres.16245
  • Open Access
    Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice
    PHILIPPE COLLERY, BERNHARD MICHALKE, MARIANNA LUCIO, DIDIER VARLET, JEAN-MARIE GUIGONIS, JEAN-CLAUDE SCIMECA, HEIDY SCHMID-ANTOMARCHI and ANNIE SCHMID-ALLIANA
    Anticancer Research March 2023, 43 (3) 1017-1023; DOI: https://doi.org/10.21873/anticanres.16246
  • You have access
    Epigallocatechin Gallate Inhibits Cell Growth and Hedgehog Signalling in Human Rhabdomyosarcoma Cell Lines
    BENJAMIN F.B. MAYER, MATIAS J. STAGNO, JÖRG FUCHS, STEVEN W. WARMANN and EVI SCHMID
    Anticancer Research March 2023, 43 (3) 1025-1030; DOI: https://doi.org/10.21873/anticanres.16247
  • You have access
    Modulatory Activity of the Copper Chelate, Copper N-(2-Hydroxy Acetophenone) Glycinate, in ABC-transporter-expressing Cell Lines
    EVA-MARIA HARTINGER, ANNE MAHRINGER, SOUMITRA KUMAR CHOUDHURI, GERT FRICKER and THOMAS EFFERTH
    Anticancer Research March 2023, 43 (3) 1031-1041; DOI: https://doi.org/10.21873/anticanres.16248
  • You have access
    Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors
    KEITA OGAWA, TETSUHIRO CHIBA, MASATO NAKAMURA, JUN ARAI, JIAQI ZHANG, YAOJIA MA, NA QIANG, JUNJIE AO, SAE YUMITA, TAKAMASA ISHINO, MOTOYASU KAN, TERUNAO IWANAGA, MIYUKI NAKAGAWA, KISAKO FUJIWARA, TAKAFUMI SAKUMA, HIROAKI KANZAKI, KEISUKE KOROKI, YUKO KUSAKABE, KAZUFUMI KOBAYASHI, NAOYA KANOGAWA, SOICHIRO KIYONO, TAKAYUKI KONDO, RYO NAKAGAWA, SADAHISA OGASAWARA, RYOSUKE MUROYAMA, SHINGO NAKAMOTO, TATSUO KANDA, HITOSHI MARUYAMA, JUN KATO, SHOJI MATSUMOTO, TAKAYOSHI ARAI, SHINICHIRO MOTOHASHI and NAOYA KATO
    Anticancer Research March 2023, 43 (3) 1043-1052; DOI: https://doi.org/10.21873/anticanres.16249
  • You have access
    Specific Aptamer Functionalization of Dense Ceramic by Click Chemistry Towards Circulating Tumor Cells Apheresis
    GUISLAINE BARRIERE, MICHEL RIGAUD, CLEMENT ARRAT, HELOÏSE COLOMBI and EVELYNE POLI
    Anticancer Research March 2023, 43 (3) 1053-1064; DOI: https://doi.org/10.21873/anticanres.16250
  • Open Access
    Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
    GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE
    Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
  • You have access
    Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines
    HIROTAKA NAKAYAMA, NAO SAITO, RIKA KASAJIMA, NOBUYASU SUGANUMA, YASUSHI RINO, KATSUHIKO MASUDO, HARUHIKO YAMAZAKI, SOJI TODA, KAZUMASA SEKIHARA, HIROYUKI IWASAKI and DAISUKE HOSHINO
    Anticancer Research March 2023, 43 (3) 1073-1077; DOI: https://doi.org/10.21873/anticanres.16252
  • You have access
    Chemokine (C-C motif) Ligand 2 Is Regulated Through the EGFR/Src Pathway in HER2-positive Breast Cancer Cells
    DAEUN YOU, HYUNGJOO KIM, YISUN JEONG, SUN YOUNG YOON, EUNJI LO, JEONG EON LEE and SANGMIN KIM
    Anticancer Research March 2023, 43 (3) 1079-1089; DOI: https://doi.org/10.21873/anticanres.16253
  • You have access
    Isophysalin A Inhibits the Stemness of Breast Cancer Cells Possibly via Stat3 and IL-6 Signaling
    YU-CHAN KO, HACK SUN CHOI, SU-LIM KIM and DONG-SUN LEE
    Anticancer Research March 2023, 43 (3) 1091-1101; DOI: https://doi.org/10.21873/anticanres.16254
  • You have access
    Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells via Strong P-gp Inhibition
    JAE HYEON PARK, JI SUN LEE, JOO KYUNG SHIN, SWATI SHARMA, HYUNG SIK KIM and SUNGPIL YOON
    Anticancer Research March 2023, 43 (3) 1103-1112; DOI: https://doi.org/10.21873/anticanres.16255
  • You have access
    5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells
    TAKANOBU NADAI, KATSUYA NARUMI, YUTO MUKAI, HINATA UEDA, AYAKO FURUGEN, YOSHITAKA SAITO and MASAKI KOBAYASHI
    Anticancer Research March 2023, 43 (3) 1113-1120; DOI: https://doi.org/10.21873/anticanres.16256
  • You have access
    A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model
    SHINJI KOBUCHI, MOTOI TSUDA, MAKI OKAMURA, TAKANORI NAKAMURA and YUKAKO ITO
    Anticancer Research March 2023, 43 (3) 1121-1130; DOI: https://doi.org/10.21873/anticanres.16257
  • You have access
    Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide
    YURIKA NAKAGAWA-SAITO, YUTA MITOBE, KEITA TOGASHI, SHUHEI SUZUKI, ASUKA SUGAI, CHIFUMI KITANAKA and MASASHI OKADA
    Anticancer Research March 2023, 43 (3) 1131-1138; DOI: https://doi.org/10.21873/anticanres.16258
  • You have access
    Dihydroartemisinin Induced Apoptosis and Synergized With Chemotherapy in Pleural Effusion Lymphoma Cells
    PLOYPLOEN PHIKULSOD, RYUSHO KARIYA, JUTATIP PANAAMPON and SEIJI OKADA
    Anticancer Research March 2023, 43 (3) 1139-1148; DOI: https://doi.org/10.21873/anticanres.16259
  • You have access
    Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression
    XUE-QUAN FANG, SEONGHOON LEE, YOUNG-SEON KIM, GA EUL HAN, CHANG-HOON LIM and JI-HONG LIM
    Anticancer Research March 2023, 43 (3) 1149-1157; DOI: https://doi.org/10.21873/anticanres.16260
  • You have access
    Down-regulating Effect of a Standardized Extract of Cultured Lentinula edodes mycelia on Cortactin in Prostate Cancer Cells Is Dependent on Malignant Potential
    SHIN-NOSUKE YAMASHITA, YOSHIATSU TANAKA, TAKAO KITAGAWA, BYRON BARON, KAZUHIRO TOKUDA, DURGA PAUDEL, KOJI NAKAGAWA, TOHRU OHTA, JUN-ICHI HAMADA, MASANOBU KOBAYASHI, HIROKI NAGAYASU and YASUHIRO KURAMITSU
    Anticancer Research March 2023, 43 (3) 1159-1166; DOI: https://doi.org/10.21873/anticanres.16261
  • You have access
    Hinokitiol Inhibits the Viability of Oral Squamous Carcinoma Cells by Inducing Apoptosis and Autophagy
    HSIN-CHIEH LIN, CHIH-CHUN WANG, CHING-FANG WU, YUAN-HO LIN, WEI-CHANG LEE, PO-JEN CHEN, YU CHANG and YU-CHIEH SU
    Anticancer Research March 2023, 43 (3) 1167-1173; DOI: https://doi.org/10.21873/anticanres.16262
  • You have access
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
    SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG
    Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
  • You have access
    Oncolytic Effect of a Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA in an Osteosarcoma Mouse Model
    TOMOHIKO SAKUDA, TADAHIKO KUBO, MUHAMMAD PHETRUS JOHAN, TAISUKE FURUTA, TAKEMASA SAKAGUCHI and NOBUO ADACHI
    Anticancer Research March 2023, 43 (3) 1185-1191; DOI: https://doi.org/10.21873/anticanres.16264
  • You have access
    Fluoxetine Inhibits STAT3-mediated Survival and Invasion of Osteosarcoma Cells
    WEI-TING CHEN, YUAN-HSIN TSAI, PEGGY TAN, FEI-TING HSU, HUI-MIN DAVID WANG, WEI-CHIN LIN, FENG-HUEI LIN and CHING-TE WU
    Anticancer Research March 2023, 43 (3) 1193-1199; DOI: https://doi.org/10.21873/anticanres.16265
  • You have access
    Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells
    YA-HUI HUANG and CHAU-TING YEH
    Anticancer Research March 2023, 43 (3) 1201-1206; DOI: https://doi.org/10.21873/anticanres.16266
  • You have access
    Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells
    SEVERINA SEMKOVA, BILIANA NIKOLOVA, IANA TSONEVA, GEORGI ANTOV, DONIKA IVANOVA, ANTON ANGELOV, ZHIVKO ZHELEV and RUMIANA BAKALOVA
    Anticancer Research March 2023, 43 (3) 1207-1212; DOI: https://doi.org/10.21873/anticanres.16267
  • You have access
    Docosahexaenoic Acid Potentiates the Anticancer Effect of the Menadione/Ascorbate Redox Couple by Increasing Mitochondrial Superoxide and Accelerating ATP Depletion
    DONIKA IVANOVA, SEVERINA SEMKOVA, ZVEZDELINA YANEVA, BILIANA NIKOLOVA, ZHIVKO ZHELEV, RUMIANA BAKALOVA and ICHIO AOKI
    Anticancer Research March 2023, 43 (3) 1213-1220; DOI: https://doi.org/10.21873/anticanres.16268
  • You have access
    Gene Profiling of Cannabis-sativa-mediated Apoptosis in Human Melanoma Cells
    KANITA POOMMARAPAN, PAISAL RUMMANEETHORN, ATTASIT SRISUBAT, NUNTAKAN SUWANPIDOKKUL, PETCHPAILIN LEENUTAPHONG, THAMTHIWAT NARARATWANCHAI, SIRADA SRIHIRUN, WANTHANEE PHETCHENGKAO, KANKANIT SURIYACHAN and SALUNYA TANCHAROEN
    Anticancer Research March 2023, 43 (3) 1221-1237; DOI: https://doi.org/10.21873/anticanres.16269
  • You have access
    A Standardized Extract of Cultured Lentinula edodes mycelia Up-regulates COX-2 in Inflammation-related Malignant Progressive Fibrosarcoma Cell Clone QRsP-11
    TAKAO KITAGAWA, SHAJEDUL ISLAM, BYRON BARON, KAZUHIRO TOKUDA, DURGA PAUDEL, TOHRU OHTA, KOJI NAKAGAWA, MASANOBU KOBAYASHI, FUTOSHI OKADA and YASUHIRO KURAMITSU
    Anticancer Research March 2023, 43 (3) 1239-1244; DOI: https://doi.org/10.21873/anticanres.16270
  • You have access
    Aurelianolides from Aureliana fasciculata var. fasciculata Trigger Apoptosis With Caspase Activation in Human Leukemia Cells
    GUSTAVO WERNECK DE SOUZA E SILVA, ANDRÉ MESQUITA MARQUES, ANA PAULA GREGÓRIO ALVES FONTÃO, SIMONE CRISTINA DE MOURA LIMA, MARIA AUXILIADORA COELHO KAPLAN, MARIA RAQUEL FIGUEIREDO and ANDRÉ LUIZ FRANCO SAMPAIO
    Anticancer Research March 2023, 43 (3) 1245-1253; DOI: https://doi.org/10.21873/anticanres.16271
  • Open Access
    Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
    PASCALE ALICIA HOELL, KHALED ELSAYAD, HENDRIK BERSSENBRUEGGE, DOMINIK HERING, CHRISTOPHER KITTEL, JOHANNES KLEINHEINZ, ANNALEN BLECKMANN, GEORG EVERS, EVA WARDELMANN, CLAUDIA RUDACK and HANS THEODOR EICH
    Anticancer Research March 2023, 43 (3) 1255-1263; DOI: https://doi.org/10.21873/anticanres.16272

Clinical Studies

  • Open Access
    Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA
    Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
  • Open Access
    Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
    SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER
    Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
  • You have access
    Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
    AKIMITSU MAEDA, HITOSHI ANDO, KEI IRIE, NAOYA HASHIMOTO, JUN-ICHI MORISHIGE, SHOJI FUKUSHIMA, HIROMICHI EBI, KOSAKU UCHIDA, HIROJI IWATA and MASATAKA SAWAKI
    Anticancer Research March 2023, 43 (3) 1283-1289; DOI: https://doi.org/10.21873/anticanres.16275
  • You have access
    Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data
    VITTORIO GEBBIA, FEDERICA MARTORANA, MARIA VITA SANÒ, MARIA ROSARIA VALERIO, FRANCESCO GIOTTA, MASSIMILIANO SPADA, DARIO PIAZZA, MICHELE CARUSO and PAOLO VIGNERI
    Anticancer Research March 2023, 43 (3) 1291-1299; DOI: https://doi.org/10.21873/anticanres.16276
  • You have access
    Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy
    MOTOHIKO KINOMURA, HIROTOSHI IIHARA, HIRONORI FUJII, CHIEMI HIROSE, JUNKI ENDO, KOMEI YANASE, TOSHIYA INUI, DAIZO KAITO, YUKA SASAKI, TAKENOBU GOMYO, CHIZURU SAKAI-MASUDA, DAISUKE KAWAE, YU KITAMURA, MASACHIKA FUKUI, RYO KOBAYASHI, YASUSHI OHNO and AKIO SUZUKI
    Anticancer Research March 2023, 43 (3) 1301-1307; DOI: https://doi.org/10.21873/anticanres.16277
  • You have access
    Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer
    DAISUKE SHIMIZU, KAZUSHI MIYATA, MASAHIDE FUKAYA, SHIZUKI SUGITA and TOMOKI EBATA
    Anticancer Research March 2023, 43 (3) 1309-1315; DOI: https://doi.org/10.21873/anticanres.16278
  • You have access
    ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma
    DAICHI ENOMOTO, KAZUHIRO YAMAMOTO, YUKI MATSUMOTO, ASAMI MORIOKA, TOMOHIRO OMURA, SHOHEI KOMATSU, YOSHIHIKO YANO, TAKUMI FUKUMOTO and IKUKO YANO
    Anticancer Research March 2023, 43 (3) 1317-1323; DOI: https://doi.org/10.21873/anticanres.16279
  • You have access
    Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO
    Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
  • You have access
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
    JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG
    Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
  • You have access
    Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER
    TAKUYA IMATOH, TAICHI MATSUMOTO, YUTAKA HARAMAKI and KEISUKE MIGITA
    Anticancer Research March 2023, 43 (3) 1341-1349; DOI: https://doi.org/10.21873/anticanres.16282
  • You have access
    Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
    RYUNOSUKE NAKAGAWA, HIROAKI IWAMOTO, RENATO NAITO, SUGURU KADOMOTO, HIROSHI YAEGASHI, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI
    Anticancer Research March 2023, 43 (3) 1351-1359; DOI: https://doi.org/10.21873/anticanres.16283
  • You have access
    Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma
    JEN-YU CHENG, BING-SHEN HUANG, YEN-YANG CHEN, CHIH-CHI WANG and YEN-HAO CHEN
    Anticancer Research March 2023, 43 (3) 1361-1371; DOI: https://doi.org/10.21873/anticanres.16284
  • You have access
    Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series
    MAKO IKEDA, YUKI KATAOKA, TOMOE TAJI, HIROFUMI SUWA and HIDEKO NAKAGOSHI
    Anticancer Research March 2023, 43 (3) 1373-1375; DOI: https://doi.org/10.21873/anticanres.16285
  • You have access
    Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG
    Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286

Corrigenda

  • Open Access
    Corrigenda
    Anticancer Research March 2023, 43 (3) 1385;
Back to top
PreviousNext

In this issue

Anticancer Research: 43 (3)
Anticancer Research
Vol. 43, Issue 3
March 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)

Issue highlights

  • Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators
  • Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
  • 7,8-Diacetoxy-3-(4-methylsulfonylphenyl)-4-phenylcoumarin Induces ROS-dependent Cell Death in the A549 Human Lung Cancer Cell Line
  • Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
Sign up for alerts

Jump to

  • Reviews
  • Experimental Studies
  • Clinical Studies
  • Corrigenda
  • Top Topics
  • Most Cited
  • Most Read
Loading
Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies
The Association of Solar Ultraviolet B (UVB) with Reducing Risk of Cancer: Multifactorial Ecologic Analysis of Geographic Variation in Age-adjusted Cancer Mortality Rates
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
Vitamin D Supplement Doses and Serum 25-Hydroxyvitamin D in the Range Associated with Cancer Prevention
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire